Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.
Percutaneous coronary intervention (PCI) has become the most common revascularization procedure for coronary artery disease. The use of stents has reduced the rate of restenosis by preventing elastic recoil and negative remodeling. However, in-stent restenosis remains one of the major drawbacks of this procedure. Drug-eluting stents (DESs) have proven to be effective in reducing the risk of late restenosis, but the use of currently marketed DESs presents safety concerns, including the non-specificity of therapeutics, incomplete endothelialization leading to late thrombosis, the need for long-term anti-platelet agents, and local hypersensitivity to polymer delivery matrices. In addition, the current DESs lack the capacity for adjustment of the drug dose and release kinetics appropriate to the disease status of the treated vessel. The development of efficacious therapeutic strategies to prevent and inhibit restenosis after PCI is critical for the treatment of coronary artery disease. The administration of drugs using biodegradable polymer nanoparticles as carriers has generated immense interest due to their excellent biocompatibility and ability to facilitate prolonged drug release. Despite the potential benefits of nanoparticles as smart drug delivery and diagnostic systems, much research is still required to evaluate potential toxicity issues related to the chemical properties of nanoparticle materials, as well as to their size and shape. This review describes the molecular mechanism of coronary restenosis, the use of DESs, and progress in nanoparticle drug- or gene-eluting stents for the prevention and treatment of coronary restenosis.
1. Department of Cardiology, Institute of Cardiovascular Diseases, the First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Rui-Xing
RX
Yin
2. Department of Molecular Biology, Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
De-Zhai
DZ
Yang
1. Department of Cardiology, Institute of Cardiovascular Diseases, the First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Jin-Zhen
JZ
Wu
D035843:Biomedical Research / Q000639:trends; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods*; D023903:Coronary Restenosis / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D053758:Nanoparticles / Q000627:therapeutic use*; D015607:Stents
D002317:Cardiovascular Agents
Coronary artery disease; Nanoparticle.; Restenosis; Stenosis; Stents